Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 9:2019:9628536.
doi: 10.1155/2019/9628536. eCollection 2019.

Challenges and Controversies in Human Mesenchymal Stem Cell Therapy

Barbara Lukomska  1 , Luiza Stanaszek  1 , Ewa Zuba-Surma  2 , Pawel Legosz  3 , Sylwia Sarzynska  3 , Katarzyna Drela  1
Affiliations
Review

Challenges and Controversies in Human Mesenchymal Stem Cell Therapy

Barbara Lukomska et al. Stem Cells Int. .

Abstract

Stem cell therapy is being intensely investigated within the last years. Expectations are high regarding mesenchymal stem cell (MSC) treatment in translational medicine. However, many aspects concerning MSC therapy should be profoundly defined. Due to a variety of approaches that are investigated, potential effects of stem cell therapy are not transparent. On the other hand, most results of MSC administration in vivo have confirmed their safety and showed promising beneficial outcomes. However, the therapeutic effects of MSC-based treatment are still not spectacular and there is a potential risk related to MSC applications into specific cell niche that should be considered in long-term observations and follow-up outcomes. In this review, we intend to address some problems and critically discuss the complex nature of MSCs in the context of their effective and safe applications in regenerative medicine in different diseases including graft versus host disease (GvHD) and cardiac, neurological, and orthopedic disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The scheme of potential risks of adverse events during MSC transplantation.
See this image and copyright information in PMC

References

    1. Squillaro T., Peluso G., Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplantation. 2016;25(5):829–848. doi: 10.3727/096368915X689622. - DOI - PubMed
    1. Nowakowski A., Walczak P., Janowski M., Lukomska B. Genetic engineering of mesenchymal stem cells for regenerative medicine. Stem Cells and Development. 2015;24(19):2219–2242. doi: 10.1089/scd.2015.0062. - DOI - PubMed
    1. Crivelli B., Chlapanidas T., Perteghella S., et al. Mesenchymal stem/stromal cell extracellular vesicles: from active principle to next generation drug delivery system. Journal of Controlled Release. 2017;262:104–117. doi: 10.1016/j.jconrel.2017.07.023. - DOI - PubMed
    1. Park W. S., Ahn S. Y., Sung S. I., Ahn J.-Y., Chang Y. S. Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders. Pediatric Research. 2018;83(1-2):214–222. doi: 10.1038/pr.2017.249. - DOI - PubMed
    1. Mo M., Wang S., Zhou Y., Li H., Wu Y. Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential. Cellular and Molecular Life Sciences. 2016;73(17):3311–3321. doi: 10.1007/s00018-016-2229-7. - DOI - PMC - PubMed

LinkOut - more resources